Given Imaging's FDA clearance for its PillCam Colon endoscopy capsule earlier in February will likely be the Israeli company's last big milestone as an independent entity, and possibly under Homi Shamir, its president and CEO.
Welcome to another great issue of FierceDiagnostics, our first since we merged at the end of 2013 with FierceBiomarkers. I want to assure our new and existing readers that you will still be getting the nuanced and dedicated coverage that you've grown accustomed to getting from Fierce, as the combined publication benefits both our diagnostics and biomarkers readers.
Xagenic has scored something that few diagnostics startups were able to accomplish in 2013: significant early-stage venture financing. An $18.8 million Series B round, to be exact, after an impressive $10 million Series A in January 2012.
Starting this January, FierceBiomarkers is merging with its sister publication, FierceDiagnostics. FierceDiagnostics will retain its name and brand, but coverage will expand to include the use of biomarkers as they relate to the broader diagnostics industry.
This week, we launch our latest newsletter: FierceDiagnostics. And I'll be editing and writing the publication in the weeks ahead.
Biomarkers play a major role in personalized medicine, supporting diagnosis and identifying those patients who are (or aren't) likely to respond, and supporting drugs through clinical trials.
Ulf Landegren, professor of molecular medicine at Uppsala University and vice chair of the Science for Life Laboratory (SciLifeLab), spoke with FierceBiomarkers at the BBMRI.se HandsOn: Biobanks meeting in Uppsala, Sweden, giving a taste of his views and his work in protein biomarkers. Here is a snapshot of the conversation.
As genetic tests become more widely available, some people are concerned that they are swelling the ranks and the anxiety levels of the "worried well"--the healthy people who visit the doctor to get reassurance, and can now get online genetic tests to confirm or assuage their worries.
A recently formed privately funded startup, Inform Genomics, is taking the concept of genetic markers and giving it a new twist, Ed Rubenstein, president and CEO, told FierceBiomarkers.